Literature DB >> 14753744

Expression and activity of the CDK inhibitor p57Kip2 in chondrocytes undergoing hypertrophic differentiation.

Matthew C Stewart1, Renata M Kadlcek, Paul D Robbins, James N MacLeod, R Tracy Ballock.   

Abstract

UNLABELLED: Growth plates of p57-null mice exhibit several abnormalities, including loss of collagen type X (CollX) expression. The phenotypic consequences of p57 expression were assessed in an in vitro model of hypertrophic differentiation. Adenoviral p57 expression was not sufficient for CollX expression but did augment induction of CollX by BMP-2.
INTRODUCTION: During hypertrophic differentiation, chondrocytes pass from an actively proliferative state to a postmitotic, hypertrophic phenotype. The induction of growth arrest is a central feature of this phenotypic transition. Mice lacking the cyclin dependent-kinase inhibitor p57Kip2 exhibit several developmental abnormalities including chondrodysplasia. Although growth plate chondrocytes in p57-null mice undergo growth arrest, they do not express collagen type X, a specific marker of the hypertrophic phenotype. This study was carried out to investigate the link between p57 expression and the induction of collagen type X in chondrocytes and to determine whether p57 overexpression is sufficient for the induction of hypertrophic differentiation.
MATERIALS AND METHODS: Neonatal rat epiphyseal or growth plate chondrocytes were maintained in an aggregate culture model, in defined, serum-free medium. Protein and mRNA levels were monitored by Western and Northern blot analyses, respectively. Proliferative activity was assessed by fluorescent measurement of total DNA and by 3H-thymidine incorporation rates. An adenoviral vector was used to assess the phenotypic consequences of p57 expression. RESULTS AND
CONCLUSIONS: During in vitro hypertrophic differentiation, levels of p57 mRNA and protein were constant despite changes in chondrocyte proliferative activity and the induction of hypertrophic-specific genes in response to bone morphogenetic protein (BMP)-2. Adenoviral p57 overexpression induced growth arrest in prehypertrophic epiphyseal chondrocytes in a dose-dependent manner but was not sufficient for the induction of collagen type X, either alone or when coexpressed with the related CDKI p21Cip1. Similar results were obtained with more mature tibial growth plate chondrocytes. p57 overexpression did augment collagen type X induction by BMP-2. These data indicate that p57-mediated growth arrest is not sufficient for expression of the hypertrophic phenotype, but rather it occurs in parallel with other aspects of the differentiation pathway. Our findings also suggest a contributing role for p57 in the regulation of collagen type X expression in differentiating chondrocytes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14753744     DOI: 10.1359/JBMR.0301209

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  10 in total

1.  Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity.

Authors:  Y Ma; W D Cress
Journal:  Oncogene       Date:  2006-12-18       Impact factor: 9.867

2.  CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner.

Authors:  Yihong Ma; Lu Chen; Gabriela M Wright; Smitha R Pillai; Srikumar P Chellappan; W Douglas Cress
Journal:  J Biol Chem       Date:  2010-01-27       Impact factor: 5.157

3.  Cyclic GMP-dependent protein kinase II is a molecular switch from proliferation to hypertrophic differentiation of chondrocytes.

Authors:  Hirotaka Chikuda; Fumitaka Kugimiya; Kazuto Hoshi; Toshiyuki Ikeda; Toru Ogasawara; Takashi Shimoaka; Hirotaka Kawano; Satoru Kamekura; Atsuko Tsuchida; Norihide Yokoi; Kozo Nakamura; Kajuro Komeda; Ung-Il Chung; Hiroshi Kawaguchi
Journal:  Genes Dev       Date:  2004-10-01       Impact factor: 11.361

4.  Cooperation between p27 and p107 during endochondral ossification suggests a genetic pathway controlled by p27 and p130.

Authors:  Nancy Yeh; Jeffrey P Miller; Tripti Gaur; Terence D Capellini; Janko Nikolich-Zugich; Carmen de la Hoz; Licia Selleri; Timothy G Bromage; Andre J van Wijnen; Gary S Stein; Jane B Lian; Anxo Vidal; Andrew Koff
Journal:  Mol Cell Biol       Date:  2007-05-14       Impact factor: 4.272

5.  Developmental mechanisms in articular cartilage degradation in osteoarthritis.

Authors:  Elena V Tchetina
Journal:  Arthritis       Date:  2010-12-29

6.  A new technique for seeding chondrocytes onto solvent-preserved human meniscus using the chemokinetic effect of recombinant human bone morphogenetic protein-2.

Authors:  Hiroaki Minehara; Ken Urabe; Kouji Naruse; Alexander T Mehlhorn; Kentaroo Uchida; Norbert P Südkamp; Moritoshi Itoman
Journal:  Cell Tissue Bank       Date:  2010-06-17       Impact factor: 1.522

7.  Cip/Kip cyclin-dependent protein kinase inhibitors and the road to polyploidy.

Authors:  Zakir Ullah; Chrissie Y Lee; Melvin L Depamphilis
Journal:  Cell Div       Date:  2009-06-02       Impact factor: 5.130

8.  The PI3K pathway regulates endochondral bone growth through control of hypertrophic chondrocyte differentiation.

Authors:  Veronica Ulici; Katie D Hoenselaar; J Ryan Gillespie; Frank Beier
Journal:  BMC Dev Biol       Date:  2008-04-11       Impact factor: 1.978

9.  mTORC1 regulates PTHrP to coordinate chondrocyte growth, proliferation and differentiation.

Authors:  Bo Yan; Zhongmin Zhang; Dadi Jin; Chen Cai; Chunhong Jia; Wen Liu; Ting Wang; Shengfa Li; Haiyan Zhang; Bin Huang; Pinglin Lai; Hua Wang; Anling Liu; Chun Zeng; Daozhang Cai; Yu Jiang; Xiaochun Bai
Journal:  Nat Commun       Date:  2016-04-04       Impact factor: 14.919

10.  Notch signaling indirectly promotes chondrocyte hypertrophy via regulation of BMP signaling and cell cycle arrest.

Authors:  Xifu Shang; Jinwu Wang; Zhengliang Luo; Yongjun Wang; Massimo M Morandi; John V Marymont; Matthew J Hilton; Yufeng Dong
Journal:  Sci Rep       Date:  2016-05-05       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.